A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58831878

Enrollment

119

Registered

2001-07-01

Start date

1992-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkin's) cancer Cancer Lymphoma (non-Hodgkin's)

Interventions

All patients receive induction therapy and conventional chemotherapy regimens. Patients achieving complete remission or partial remission are randomised to either: 1. R

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically documented lymphoblastic lymphoma 2. No prior chemotherapy or radiotherapy, except chemotherapy given for immediate relief of symptoms at presentation 3. Age 15 or over 4. All stages 5. No circulating blasts 6. Normal values for renal and hepatic function, unless directly attributable to lymphoma 7. Normal cardiac function 8. No evidence of Human Immunodeficiency Virus (HIV) infection

Exclusion criteria

Exclusion criteria: Patients will be excluded if they have HLA-identical siblings who are undergoing allogenic bone marrow transplantation. These patients should be registered with the trials office but will not be randomised.

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026